Prellis Biologics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Prellis Biologics is a private, preclinical-stage biotech leveraging a unique convergence of 3D bioprinting, immune system replication, and AI/ML to revolutionize antibody discovery. Its EXIS™ platform generates diverse, fully human antibody leads with high hit rates against difficult target classes like GPCRs, while reducing immunogenicity risk. Founded in 2016 and based in San Francisco, the company has secured significant venture funding and established a key partnership with Eli Lilly, positioning it to advance its internal pipeline and platform collaborations.

AntibodiesBiologicsTissue Engineering

Technology Platform

EXIS™ platform integrates 3D bioprinted lymph node organoids (LNO™) with human immune cell diversity and AI/ML to discover and optimize fully human antibodies in vitro.

Opportunities

The platform addresses key industry challenges by enabling high hit rates against difficult target classes (e.g., GPCRs) and generating fully human antibodies with low immunogenicity risk, potentially reducing clinical failure rates.

The growing demand for novel biologics and the shift away from animal-based discovery create a favorable market environment for its technology.

Risk Factors

Key risks include the need for full clinical validation of the platform's output, intense competition in the AI-driven drug discovery space, and the operational complexity of scaling an integrated bioprinting and AI platform.

As a private company, it remains dependent on raising additional capital to fund operations.

Competitive Landscape

Prellis competes in the crowded field of AI-powered antibody discovery, facing off against companies using display technologies, single-cell sequencing, and computational design. Its differentiation lies in the unique integration of 3D bioprinted organoids to replicate human immune system biology, a approach less common than purely computational or display-based methods.

More companies in Biologics / Biosimilars →More companies in United States →